Hebach
Andreas Hebach, Ludwigsburg DE
Patent application number | Description | Published |
---|---|---|
20110247952 | PRESSURE-RELIEF VALVE OF A HOUSING FOR AN ELECTRICAL/ELECTRONIC UNIT - The invention relates to a pressure-relief valve of a housing for an electrical/electronic unit, particularly for a housing of a control unit of a motor vehicle, comprising a pressure equalization element, which comprises a membrane. It is provided that at least one hydrophobic layer ( | 10-13-2011 |
Christina Hebach, Basel CH
Patent application number | Description | Published |
---|---|---|
20120065183 | Tetrahydro-Pyrido-Pyrimidine Derivatives - The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I), | 03-15-2012 |
20140128370 | Tetrahydro-Pyrido-Pyrimidine Derivatives - The invention relates to substituted tetrahydro-pyrido-pyrimidine derivatives of the formula (I), | 05-08-2014 |
Christina Hebach, Muenchenstein CH
Patent application number | Description | Published |
---|---|---|
20140142105 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE - The invention relates to novel trifluoromethyl-oxadiazole derivatives of formula (I), and pharmaceutically acceptable salts thereof, (I) in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, pharmaceutical combinations thereof, and their use as medicaments, particularly for the treatment of neurodegeneration, muscle atrophy or metabolic syndrome via inhibition of HDAC4. | 05-22-2014 |
20140249139 | Quinazoline Derivatives - The invention relates to substituted quinazoline derivative of the formula (I), wherein A, X | 09-04-2014 |
Christina Hebach, Muenchenstein DE
Patent application number | Description | Published |
---|---|---|
20140329825 | NOVEL TRIFLUOROMETHYL-OXADIAZOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE - The invention relates to novel trifluoromethyl-oxadiazole derivatives of formula (I), and pharmaceutically acceptable salts thereof, in which all of the variables are as defined in the specification, pharmaceutical compositions thereof, pharmaceutical combinations thereof, and their use as medicaments, particularly for the treatment of neurodegeneration, muscle atrophy or diabetes/metabolic syndrome via inhibition of HDAC4. | 11-06-2014 |